Interim Report, January – March 2014*
Financial summary for the first quarter · Net turnover totalled SEK 208.2 million (SEK 178.1 m), SEK 161.7 million of which comprised royalties for simeprevir. · A deferred tax receivable and a tax income of SEK 196.8 million are reported during the quarter, corresponding to a capitalisation of the entire loss carry forward related to Medivir AB, as of 31 March 2014. · The profit/loss after tax was SEK 283.8 million (SEK 71.1 m). · Basic and diluted earnings per share totalled SEK 9.08 (SEK 2.27) and SEK 9.01 (SEK 2.24), respectively. · The cash flow from operating